Get the Stockscreener App
0.6955
3.79%
-0.027
Cosmos Health Inc stock is traded at $0.6955, with a volume of 592.84K.
It is down -3.79% in the last 24 hours and up +2.37% over the past month.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
See More
Previous Close:
$0.7225
Open:
$0.71
24h Volume:
592.84K
Relative Volume:
1.37
Market Cap:
$16.81M
Revenue:
$56.04M
Net Income/Loss:
$-20.39M
P/E Ratio:
-0.285
EPS:
-2.44
Net Cash Flow:
$-6.84M
1W Performance:
-1.82%
1M Performance:
+2.37%
6M Performance:
-35.64%
1Y Performance:
-14.35%
1-Day Range:
$0.6801
$0.83
1-Week Range:
$0.655
$0.83
52-Week Range:
$0.4677
$1.58
Cosmos Health Inc Stock (COSM) Company Profile
Name
Cosmos Health Inc
Sector
Industry
Phone
312-536-3102
Address
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Compare COSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COSM
Cosmos Health Inc
|
0.7003 | 16.81M | 56.04M | -20.39M | -6.84M | -2.44 |
|
MCK
Mckesson Corporation
|
600.28 | 77.79B | 330.19B | 2.54B | 4.31B | 19.31 |
|
COR
Cencora Inc
|
248.54 | 47.73B | 293.96B | 1.51B | 3.00B | 7.51 |
|
CAH
Cardinal Health Inc
|
127.83 | 30.95B | 222.16B | 1.31B | -486.00M | 5.36 |
|
HSIC
Henry Schein Inc
|
79.09 | 9.32B | 12.50B | 314.00M | 421.00M | 2.44 |
|
PDCO
Patterson Companies Inc
|
31.02 | 2.72B | 6.55B | 155.22M | -823.13M | 1.71 |
Cosmos Health Inc Stock (COSM) Latest News
Cosmos Health Pockets 10-Year Manufacturing Deal With Provident Pharmaceuticals - Yahoo Finance
Cosmos Health secures a 10-year contract with Provident - Investing.com India
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility - Yahoo Finance
Cosmos Health Inc [COSM] Shares Fall Approximately -34.36% Over the Year - Knox Daily
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar - ACCESS Newswire
Major Middle East Expansion: Cosmos Health Lands Exclusive $578K Qatar Distribution Contract - StockTitan
Cosmos Health Inc (COSM)’s stock price range in the last year - US Post News
Deeper Dive: Understanding Cosmos Health Inc (COSM) Through its Various Ratios - The Dwinnex
Cosmos Health Files Patent Application for Multiple Sclerosis Treatment -February 05, 2025 at 12:02 pm EST - Marketscreener.com
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market - ACCESS Newswire
Revolutionary MS Treatment Patent: Cosmos Health's AI Platform Targets $26B Market - StockTitan
Cosmos health CEO Grigorios Siokas acquires $34,000 in stock - MSN
Cosmos health CEO Grigorios Siokas acquires $34,000 in stock By Investing.com - Investing.com Australia
Cosmos Health files patent for allergy inflammation treatment - MSN
Cosmos Health : Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow - Marketscreener.com
Major European Bank Backs Cosmos Health with €2.2M Strategic Financing Deal - StockTitan
Cosmos Health expands distribution of Avian Influenza kits - MSN
Cosmos Health files patent for allergy inflammation treatment By Investing.com - Investing.com UK
Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion - Yahoo Finance
Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company - ACCESS Newswire
Cosmos Health Files AI-Powered Patent for Revolutionary Allergy Treatment - StockTitan
Taglich Brothers Initiates Coverage of Cosmos Health Inc. - ACCESS Newswire
Cosmos health CEO Grigorios Siokas acquires shares worth $29,999 - MSN
Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21% - ACCESS Newswire
Cosmos Health Inc. Enters into Patent and Technology License Agreement with DocPharma Single SA. (Greece) - Defense World
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait - Lelezard
Cosmos health CEO Grigorios Siokas acquires shares worth $29,999 By Investing.com - Investing.com South Africa
Cosmos Health expands distribution of Avian Influenza kits By Investing.com - Investing.com UK
Cosmos Health Expands Virax PCR Kit Distribution to Saudi Arabia, UAE in Major Gulf Growth - StockTitan
Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share - ACCESS Newswire
Fast-paced Momentum Stock Cosmos Health Inc. (COSM) Is Still Trading at a Bargain - Yahoo Canada Finance
Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million - Marketscreener.com
Cosmos Health CEO acquires $25,000 in stock through debt exchange - MSN
Cosmos Health secures exclusive cancer patent license By Investing.com - Investing.com Australia
Cosmos Health secures exclusive cancer patent license - Investing.com
Cosmos Health secures rights to two anticancer drugs By Investing.com - Investing.com Australia
Cosmos Health secures rights to two anticancer drugs - Investing.com
Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cance - PharmiWeb.com
Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Pro - News Channel Nebraska
Cosmos Health CEO Shows Conviction With $425,000 Share Purchase, Total Investment Tops $17M - StockTitan
Cosmos Health CEO acquires $25,000 in stock through debt exchange By Investing.com - Investing.com South Africa
Head-To-Head Comparison: Aceto (OTCMKTS:ACETQ) versus Cosmos Health (NASDAQ:COSM) - Defense World
Aceto (OTCMKTS:ACETQ) versus Cosmos Health (NASDAQ:COSM) Financial Comparison - Defense World
Cosmos health CEO Siokas acquires shares in $40,000 debt exchange - MSN
Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units - ACCESS Newswire
Market Might Still Lack Some Conviction On Cosmos Health Inc. (NASDAQ:COSM) Even After 31% Share Price Boost - Simply Wall St
Cosmos health CEO Siokas acquires shares in $40,000 debt exchange By Investing.com - Investing.com Australia
Cosmos Health CEO Grigorios Siokas acquires $50,000 in stock - MSN
Cosmos Health Inc Stock (COSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cosmos Health Inc Stock (COSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Siokas Grigorios | Chief Executive Officer |
Jan 22 '25 |
Buy |
0.77 |
38,900 |
30,000 |
4,203,689 |
| Siokas Grigorios | Chief Executive Officer |
Jan 17 '25 |
Buy |
0.86 |
29,158 |
25,000 |
4,164,789 |
| Siokas Grigorios | Chief Executive Officer |
Jan 16 '25 |
Buy |
0.83 |
47,904 |
40,000 |
4,135,631 |
| Siokas Grigorios | Chief Executive Officer |
Jan 15 '25 |
Buy |
0.80 |
62,500 |
50,000 |
4,087,727 |
| Siokas Grigorios | Chief Executive Officer |
Jan 14 '25 |
Buy |
0.69 |
87,247 |
60,000 |
4,025,227 |
| Siokas Grigorios | Chief Executive Officer |
Jan 13 '25 |
Buy |
0.61 |
163,666 |
100,000 |
3,937,980 |
| Terzis Georgios | Chief Financial Officer |
Dec 20 '24 |
Buy |
0.58 |
85,778 |
50,000 |
727,263 |
| Siokas Grigorios | Chief Executive Officer |
Dec 20 '24 |
Buy |
0.58 |
257,334 |
150,000 |
3,774,314 |
| Siokas Grigorios | Chief Executive Officer |
Feb 16 '24 |
Buy |
0.83 |
60,000 |
49,806 |
1,394,597 |
4.81%
7.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):